138 related articles for article (PubMed ID: 30259402)
1. Enhancement in the Transdermal and Localized Delivery of Honokiol Through Breast Tissue.
Gao X; Patel MG; Bakshi P; Sharma D; Banga AK
AAPS PharmSciTech; 2018 Nov; 19(8):3501-3511. PubMed ID: 30259402
[TBL] [Abstract][Full Text] [Related]
2. Derivatization of honokiol by integrated acetylation and methylation for improved cutaneous delivery and anti-inflammatory potency.
Fang JY; Huang TH; Hung CF; Huang YL; Aljuffali IA; Liao WC; Lin CF
Eur J Pharm Sci; 2018 Mar; 114():189-198. PubMed ID: 29241737
[TBL] [Abstract][Full Text] [Related]
3. A novel transdermal honokiol formulation based on Pluronic F127 copolymer.
Zheng X; Wang X; Gou M; Zhang J; Men K; Chen L; Luo F; Zhao X; Wei Y; Qian Z
Drug Deliv; 2010 Apr; 17(3):138-44. PubMed ID: 20175649
[TBL] [Abstract][Full Text] [Related]
4. Maximizing dermal targeting and minimizing transdermal penetration by magnolol/honokiol methoxylation.
Lin CF; Hwang TL; Al-Suwayeh SA; Huang YL; Hung YY; Fang JY
Int J Pharm; 2013 Mar; 445(1-2):153-62. PubMed ID: 23380623
[TBL] [Abstract][Full Text] [Related]
5. Anti-tumor effect of honokiol alone and in combination with other anti-cancer agents in breast cancer.
Liu H; Zang C; Emde A; Planas-Silva MD; Rosche M; Kühnl A; Schulz CO; Elstner E; Possinger K; Eucker J
Eur J Pharmacol; 2008 Sep; 591(1-3):43-51. PubMed ID: 18588872
[TBL] [Abstract][Full Text] [Related]
6. Development of a Chitosan-based Nanoparticle Formulation for Ophthalmic Delivery of Honokiol.
Deng F; Hu W; Chen H; Tang Y; Zhang L
Curr Drug Deliv; 2018; 15(4):594-600. PubMed ID: 28425869
[TBL] [Abstract][Full Text] [Related]
7. Co-delivery of honokiol, a constituent of Magnolia species, in a self-microemulsifying drug delivery system for improved oral transport of lipophilic sirolimus.
Ding W; Hou X; Cong S; Zhang Y; Chen M; Lei J; Meng Y; Li X; Li G
Drug Deliv; 2016 Sep; 23(7):2513-2523. PubMed ID: 25835221
[TBL] [Abstract][Full Text] [Related]
8. Design, Formulation and in vivo Evaluation of Novel Honokiol-Loaded PEGylated PLGA Nanocapsules for Treatment of Breast Cancer.
Haggag YA; Ibrahim RR; Hafiz AA
Int J Nanomedicine; 2020; 15():1625-1642. PubMed ID: 32210557
[TBL] [Abstract][Full Text] [Related]
9. Regulation of Mucin 1 and multidrug resistance protein 1 by honokiol enhances the efficacy of doxorubicin-mediated growth suppression in mammary carcinoma cells.
Thulasiraman P; Johnson AB
Int J Oncol; 2016 Aug; 49(2):479-86. PubMed ID: 27221150
[TBL] [Abstract][Full Text] [Related]
10. Influence of sonophoresis and chemical penetration enhancers on percutaneous transport of penbutolol sulfate.
Ita KB; Popova IE
Pharm Dev Technol; 2016 Dec; 21(8):990-995. PubMed ID: 26383739
[TBL] [Abstract][Full Text] [Related]
11. Improved solubility and pharmacokinetics of PEGylated liposomal honokiol and human plasma protein binding ability of honokiol.
Wang XH; Cai LL; Zhang XY; Deng LY; Zheng H; Deng CY; Wen JL; Zhao X; Wei YQ; Chen LJ
Int J Pharm; 2011 May; 410(1-2):169-74. PubMed ID: 21397675
[TBL] [Abstract][Full Text] [Related]
12. Chemoprevention of Breast Cancer by Transdermal Delivery of α-Santalol through Breast Skin and Mammary Papilla (Nipple).
Dave K; Alsharif FM; Islam S; Dwivedi C; Perumal O
Pharm Res; 2017 Sep; 34(9):1897-1907. PubMed ID: 28589445
[TBL] [Abstract][Full Text] [Related]
13. Zein Microneedles for Localized Delivery of Chemotherapeutic Agents to Treat Breast Cancer: Drug Loading, Release Behavior, and Skin Permeation Studies.
Bhatnagar S; Kumari P; Pattarabhiran SP; Venuganti VVK
AAPS PharmSciTech; 2018 May; 19(4):1818-1826. PubMed ID: 29616489
[TBL] [Abstract][Full Text] [Related]
14. Honokiol nanomicellar formulation produced increased oral bioavailability and anticancer effects in triple negative breast cancer (TNBC).
Godugu C; Doddapaneni R; Singh M
Colloids Surf B Biointerfaces; 2017 May; 153():208-219. PubMed ID: 28249200
[TBL] [Abstract][Full Text] [Related]
15. Synergistic antitumor effects of liposomal honokiol combined with adriamycin in breast cancer models.
Hou W; Chen L; Yang G; Zhou H; Jiang Q; Zhong Z; Hu J; Chen X; Wang X; Yuan Y; Tang M; Wen J; Wei Y
Phytother Res; 2008 Aug; 22(8):1125-32. PubMed ID: 18570244
[TBL] [Abstract][Full Text] [Related]
16. Honokiol, a phytochemical from the Magnolia plant, inhibits photocarcinogenesis by targeting UVB-induced inflammatory mediators and cell cycle regulators: development of topical formulation.
Vaid M; Sharma SD; Katiyar SK
Carcinogenesis; 2010 Nov; 31(11):2004-11. PubMed ID: 20823108
[TBL] [Abstract][Full Text] [Related]
17. Novel in situ forming hydrogel microneedles for transdermal drug delivery.
Sivaraman A; Banga AK
Drug Deliv Transl Res; 2017 Feb; 7(1):16-26. PubMed ID: 27562294
[TBL] [Abstract][Full Text] [Related]
18. Chemopreventive effects of combination of honokiol and magnolol with α-santalol on skin cancer developments.
Chilampalli C; Zhang X; Kaushik RS; Young A; Zeman D; Hildreth MB; Fahmy H; Dwivedi C
Drug Discov Ther; 2013 Jun; 7(3):109-15. PubMed ID: 23917859
[TBL] [Abstract][Full Text] [Related]
19. Combination of microneedles and microemulsions to increase celecoxib topical delivery for potential application in chemoprevention of breast cancer.
Mojeiko G; de Brito M; Salata GC; Lopes LB
Int J Pharm; 2019 Apr; 560():365-376. PubMed ID: 30772460
[TBL] [Abstract][Full Text] [Related]
20. Effects of chemical and physical enhancement techniques on transdermal delivery of 3-fluoroamphetamine hydrochloride.
Puri A; Murnane KS; Blough BE; Banga AK
Int J Pharm; 2017 Aug; 528(1-2):452-462. PubMed ID: 28633107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
